vs
i3 Verticals, Inc.（IIIV）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
i3 Verticals, Inc.的季度营收约是REGENXBIO Inc.的1.7倍（$52.7M vs $30.3M），i3 Verticals, Inc.净利率更高（0.9% vs -221.3%，领先222.3%），REGENXBIO Inc.同比增速更快（43.0% vs -14.6%），i3 Verticals, Inc.自由现金流更多（$13.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -4.7%）
Prusa i3是捷克Prusa Research公司生产的熔融沉积成型3D打印机系列，以Original Prusa i3为注册商标推出，同时也是RepRap项目的组成部分。2016年该系列就被评为全球使用率最高的3D打印机，最早由Josef Průša在2012年完成设计，2015年正式推出商用套件版本，目前最新型号同时提供散件套件和原厂组装版本，具备性价比高、易操作的优势。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
IIIV vs RGNX — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.7M | $30.3M |
| 净利润 | $484.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 3.1% | -190.0% |
| 净利率 | 0.9% | -221.3% |
| 营收同比 | -14.6% | 43.0% |
| 净利润同比 | -76.5% | -31.2% |
| 每股收益（稀释后） | $0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $52.7M | $30.3M | ||
| Q3 25 | $46.0M | $29.7M | ||
| Q2 25 | $51.9M | $21.4M | ||
| Q1 25 | $63.1M | $89.0M | ||
| Q4 24 | $52.2M | $21.2M | ||
| Q3 24 | $32.0M | $24.2M | ||
| Q2 24 | $46.2M | $22.3M | ||
| Q1 24 | $58.0M | $15.6M |
| Q4 25 | $484.0K | $-67.1M | ||
| Q3 25 | $3.1M | $-61.9M | ||
| Q2 25 | $12.9M | $-70.9M | ||
| Q1 25 | $-154.0K | $6.1M | ||
| Q4 24 | $2.1M | $-51.2M | ||
| Q3 24 | $117.9M | $-59.6M | ||
| Q2 24 | $-7.5M | $-53.0M | ||
| Q1 24 | $1.9M | $-63.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | 3.1% | -190.0% | ||
| Q3 25 | 3.2% | -176.3% | ||
| Q2 25 | -9.3% | -296.3% | ||
| Q1 25 | 8.0% | 13.6% | ||
| Q4 24 | 3.9% | -242.1% | ||
| Q3 24 | 10.6% | -256.6% | ||
| Q2 24 | -2.8% | -251.3% | ||
| Q1 24 | 3.4% | -408.8% |
| Q4 25 | 0.9% | -221.3% | ||
| Q3 25 | 6.7% | -208.3% | ||
| Q2 25 | 24.8% | -331.8% | ||
| Q1 25 | -0.2% | 6.8% | ||
| Q4 24 | 3.9% | -241.3% | ||
| Q3 24 | 368.2% | -246.3% | ||
| Q2 24 | -16.3% | -237.7% | ||
| Q1 24 | 3.2% | -405.4% |
| Q4 25 | $0.02 | $-1.30 | ||
| Q3 25 | $0.14 | $-1.20 | ||
| Q2 25 | $0.50 | $-1.38 | ||
| Q1 25 | $0.00 | $0.12 | ||
| Q4 24 | $0.08 | $-0.99 | ||
| Q3 24 | $4.93 | $-1.17 | ||
| Q2 24 | $-0.32 | $-1.05 | ||
| Q1 24 | $0.08 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $358.5M | $102.7M |
| 总资产 | $595.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $37.5M | $230.1M | ||
| Q3 25 | $66.7M | $274.2M | ||
| Q2 25 | $55.5M | $323.3M | ||
| Q1 25 | $7.7M | $267.9M | ||
| Q4 24 | $85.6M | $234.7M | ||
| Q3 24 | $86.5M | $255.5M | ||
| Q2 24 | $9.7M | $290.4M | ||
| Q1 24 | $3.1M | $338.7M |
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $12.0M | — | ||
| Q4 24 | $26.2M | — | ||
| Q3 24 | $26.2M | — | ||
| Q2 24 | $374.1M | — | ||
| Q1 24 | $369.6M | — |
| Q4 25 | $358.5M | $102.7M | ||
| Q3 25 | $389.6M | $161.5M | ||
| Q2 25 | $383.3M | $213.7M | ||
| Q1 25 | $385.2M | $274.2M | ||
| Q4 24 | $375.0M | $259.7M | ||
| Q3 24 | $379.7M | $301.4M | ||
| Q2 24 | $249.7M | $348.3M | ||
| Q1 24 | $249.3M | $390.7M |
| Q4 25 | $595.9M | $453.0M | ||
| Q3 25 | $638.4M | $525.2M | ||
| Q2 25 | $623.3M | $581.0M | ||
| Q1 25 | $646.4M | $490.9M | ||
| Q4 24 | $726.2M | $466.0M | ||
| Q3 24 | $730.7M | $519.1M | ||
| Q2 24 | $861.7M | $569.4M | ||
| Q1 24 | $625.8M | $629.2M |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.07× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $13.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 26.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 29.18× | — |
| 过去12个月自由现金流最近4个季度 | $6.5M | $-126.4M |
8季度趋势，按日历期对齐
| Q4 25 | $14.1M | $-52.3M | ||
| Q3 25 | $14.0M | $-56.0M | ||
| Q2 25 | $7.4M | $-49.3M | ||
| Q1 25 | $-27.1M | $33.6M | ||
| Q4 24 | $11.5M | $-31.6M | ||
| Q3 24 | $15.1M | $-40.5M | ||
| Q2 24 | $8.1M | $-45.5M | ||
| Q1 24 | $10.7M | $-55.5M |
| Q4 25 | $13.8M | $-52.8M | ||
| Q3 25 | $13.5M | $-56.5M | ||
| Q2 25 | $6.8M | $-49.7M | ||
| Q1 25 | $-27.6M | $32.6M | ||
| Q4 24 | $11.0M | $-32.7M | ||
| Q3 24 | $14.6M | $-40.9M | ||
| Q2 24 | $7.2M | $-46.0M | ||
| Q1 24 | $9.9M | $-56.0M |
| Q4 25 | 26.2% | -174.0% | ||
| Q3 25 | 29.5% | -189.9% | ||
| Q2 25 | 13.1% | -232.8% | ||
| Q1 25 | -43.8% | 36.6% | ||
| Q4 24 | 21.1% | -154.2% | ||
| Q3 24 | 45.6% | -168.9% | ||
| Q2 24 | 15.6% | -206.2% | ||
| Q1 24 | 17.1% | -358.5% |
| Q4 25 | 0.6% | 1.7% | ||
| Q3 25 | 0.9% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 0.9% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.9% | 2.1% | ||
| Q1 24 | 1.4% | 3.6% |
| Q4 25 | 29.18× | — | ||
| Q3 25 | 4.52× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 5.59× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
